BWX Technologies Subsidiary in Manufacturing Agreement With Boston Scientific
May 10 2021 - 7:25AM
Dow Jones News
By Chris Wack
BWX Technologies Inc. said its BWXT Medical Ltd. subsidiary has
entered into a new long-term, mutually exclusive agreement to
manufacture TheraSphere Y-90 Glass Microspheres for Boston
Scientific.
The company said TheraSphere was developed for the treatment of
patients with hepatocellular carcinoma, and is comprised of
millions of glass microspheres containing radioactive Yttrium-90,
which are delivered directly to liver tumors via catheter and
result in minimal exposure to surrounding healthy tissue.
Under the terms of the agreement, BWXT Medical will invest to
automate the production process at its Ottawa, Canada, facility,
and significantly increase capacity and dependability to support a
growing global demand for TheraSphere.
BWXT said Boston Scientific recently received Food and Drug
Administration PMA approval of TheraSphere, which expands patient
access for this technology.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
May 10, 2021 07:10 ET (11:10 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
BWX Technologies (NYSE:BWXT)
Historical Stock Chart
From Mar 2024 to Apr 2024
BWX Technologies (NYSE:BWXT)
Historical Stock Chart
From Apr 2023 to Apr 2024
